Table A1

ANCA-associated vasculitis

DiseaseAuthor, reference noNo
WGKeogh et al36810: Effective
WG/MPAStasi et al36910: 8 WG/2 MPA: Effective
WG/MPAEriksson et al3709: 7 WG/2 MPA: Effective
WG/MPAKeogh et al37111: 10 WG/1 MPA: Effective
WG/MPA/CSSSmith et al37211: 5 WG/5 MPA/1 CSS: Effective
WGAries et al3738: Granulomatous manifestations: Effective in 3; no response in 3; ineffective 2
WGBrihaye et al3748: Refractory/relapsing: Effective
WGHenes et al3756: Refractory: Effective
WGGolbin et al37628: Refractory: Effective
WGSailler et al37737: 3 WG; 19 autoimmune cytopenia; 5 autoimmune coagulation disorder; 7 cryoglobulinaemia; 2 pemphigus; 1 SLE Effective: increased incidence of SAE
ANCA vasculitisLovric et al37815: Refractory ANCA associated vasculitis: Effective
WGSeo et al3798: Effective
ANCA associatedRoccatello et al380 3817: Effective
WGMartinez Del Pero et al38234: Effective
WGGuillevin et al38321: As effective as infliximab
WGRamos-Casals et al3848: Effective
WGPalm et al3859: Effective: suppressing inflammation not airway stenosis
Refractory WGCohen et al38622: As effective as infliximab
  • ANCA, antineutrophil cytoplasmic antibodies; CSS, Churg–Strauss syndrome; MPA, microscopic polyangiitis; SAE, serious adverse event; SLE, systemic lupus erythematosus; WG, Wegener’s granulomatosis.